EUCTR2018-003340-24-IT进行中（未招募）1 期
A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) -
OXO ONCOLOGY INCORPORATED0 个研究点目标入组 295 人开始时间: 2021年1月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 295
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Phase 1 dose escalation prior to PK trigger: Able to tolerate potentially subtherapeutic doses of LOXO-305 for the 28-day DLT window in the opinion of Investigator and with documented Sponsor approval
- •All Patients:
- •2. Histologically confirmed CLL/SLL or NHL failed or intolerant to standard of care therapies
- •3. = 2 prior lines of therapy
- •4. Eastern Cooperative Oncology Group (ECOG) 0-2
- •5. At least 18 years of age
- •6. Confirmation of availability of tumor sample obtained after most recent treatment as described in Protocol Section 7.4
- •7. Adequate hematologic status, defined as the following on C1D1 prior to treatment:
- •a. Absolute neutrophil count (ANC) = 0.75× 10^9/L and not requiring growth factors; if there is documented bone marrow involvement, growth factors (pegfilgastrim preferred) may be used at any time prior to C1D1 to achieve this ANC threshold
- •b. Platelet count = 50 × 10^9/L not requiring transfusion support; if there is documented bone marrow involvement, platelet transfusions or growth factors may be used prior to 7 days before C1D1 to achieve this platelet threshold
- •c. Hemoglobin (Hb) = 8 mg/dL not requiring transfusion support or growth factors; if there is documented bone marrow involvement, growth factors (e.g., epoetin alpha) may be used at any time prior to C1D1 to achieve this Hb threshold
- •d. Adequate coagulation, defined as activated partial thromboplastin time (aPTT) and prothrombin time (PT) (international normalized ratio [INR]) not greater than 1.5 × upper limit of normal (ULN)
- •8. Adequate hepatic function, defined as:
- •a. ALT or AST = 2.5 × the ULN or = 5 × ULN with documented liver metastases
- •b. Total bilirubin = 1.5 × ULN or = 3 × ULN with documented liver metastases and/or Gilbert's Disease
- •9. Adequate renal function defined as creatinine clearance = 30 mL/minute using Cockcroft/Gault Formula: (140 – age) × body weight (kg) × 0.85 (if female) / serum creatinine (mg/dL) × 72
- •10. Ability to swallow tablets and comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation
- •11. Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following the last dose of study treatment; this may include barrier methods such as condom or diaphragm with spermicidal gel. For male subjects with a non-pregnant female partner of child-bearing potential and a woman of child-bearing potential one of the following highly effective birth control methods with a failure rate of less than 1% per year when used consistently and correctly are recommended:
- •a. Combined estrogen and progestin containing hormonal contraception associated with inhibition of ovulation given orally, intravaginally, or transdermally
- •b. Progestin-only hormonal contraception associated with inhibition of ovulation given orally, by injection, or by implant
- •c. Intrauterine device (IUD)
- •d. Intrauterine hormone-releasing system (IUS)
- •e. Bilateral tubal occlusion
- •f. Vasectomized partner
- •g. Sexual abstinence: considered a highly effective method only if defined as refraining from heterosexual intercourse during an entire period of risk associated with the study treatment. The reliability of sexual abstinence will be evaluated in relation to the duration of the study and to the usual lifestyle of the subject (CTFG 2014).
- •Birth control methods unacceptable for this clinical trial are:
排除标准
- •Phase 1 and Phase 2
- •All Patients:
- •1.Investigational agent or anticancer therapy within 5 half-lives prior to planned start of LOXO 305 except therapeutic monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of LOXO-305. In addition, no concurrent investigational therapy is permitted.
- •a.Continuation of certain standard of care anticancer therapies, including hormonal therapy for breast and prostate cancer, is allowed, provided they are not on the list of prohibited concomitant medications. Refer to Section 6.3.2 for allowed and Section 6.3.3 for prohibited medications.
- •2.Major surgery within 4 weeks prior to planned start of LOXO 305.
- •3.Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment, except for patients receiving radiation to more than 30% of the bone marrow or receiving whole brain radiotherapy, which must be completed at least 4 weeks prior to the first dose of study treatment.
- •4.Patients requiring therapeutic anticoagulation with warfarin.
- •5.Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2 at the time of starting study treatment except for alopecia.
- •6.History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T cell (CAR-T) therapy within the past 60 days (180 days before the PK trigger) or with any of the following:
- •a.active graft versus host disease (GVHD);
- •b.cytopenias from incomplete blood cell count recovery post-transplant;
- •c.need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity > Grade 1 from CAR-T therapy;
- •d.ongoing immunosuppressive therapy.
- •7.Known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be
- •eligible if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval
- •8.Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) where new therapy introduced or concomitant therapy escalated within the 4 weeks prior to study enrollment is required to maintain adequate blood counts
- •9.Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of LOXO-305, or prolongation of the QT interval corrected for heart rate (QTcF) > 470 msec on at least 2/3 consecutive electrocardiograms (ECGs), and mean QTcF > 470 msec on all 3 ECGs, during Screening. QTcF is calculated using Fridericia’s Formula (QTcF): QTcF=QT/(RR0.33).
- •a.Correction of suspected drug-induced QTcF prolongation can be attempted at the Investigator’s discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation.
- •10.Active uncontrolled systemic bacterial, viral, fungal or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the Investigator and the Sponsor makes it undesirable for the patient to participate in the trial. Screening for chronic conditions is not required.
- •11.Tested positive for Human Immunodeficiency Virus (HIV) is excluded (due to potential drug-drug interactions between anti-retroviral medica
研究者
相似试验
进行中（未招募）
1 期
An Early Phase Study with the Drug LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)MedDRA version: 20.1 Level: LLT Classification code 10008976 Term: Chronic lymphocytic leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10003908 Term: B-cell small lymphocytic lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10029547 Term: Non-Hodgkin's lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003340-24-FRoxo Oncology, Inc.190
进行中（未招募）
1 期
An Early Phase Study with the Drug LOXO-305 in Patients with PreviouslyTreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL) or Non-Hodgkin Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)and Non-Hodgkin Lymphoma (NHL)MedDRA version: 21.1Level: PTClassification code: 10003908Term: B-cell small lymphocytic lymphoma Class: 100000004864MedDRA version: 22.0Level: PTClassification code: 10029547Term: Non-Hodgkin's lymphoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104CTIS2023-509270-37-00oxo Oncology Inc.938
进行中（未招募）
1 期
An Early Phase Study with the Drug LOXO-305 in Patients with PreviouslyTreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL) or Non-Hodgkin Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)MedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10003908Term: B-cell small lymphocytic lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003340-24-GBoxo Oncology, Inc.850
进行中（未招募）
1 期
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)JPRN-jRCT2031200245Tsai E. Donald30
进行中（未招募）
1 期
A Phase 1 study on the effects of LOXO-292 (study drug) in patients with advanced solid tumorsDose escalation: Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor refractory to standard of care therapy, or for whom no standard of care therapy is available.Dose expansion: Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.MedDRA version: 20.0Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000800-59-NLoxo Oncology, Inc.570